PegIFN-2b

BIOLOGICAL5 trials

Conditions

HCV InfectionHIV InfectionsHepatitis CHepatitis C, ChronicMelanomaRenal Cell Carcinoma

Phase 1

Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)

CompletedNCT02089685

Merck Sharp & Dohme LLCMelanoma, Renal Cell Carcinoma

Start: 2014-03-17End: 2021-04-01Updated: 2022-09-13

Phase 2

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

CompletedNCT00959699

Merck Sharp & Dohme LLCHCV Infection, Hepatitis C, HIV Infections

Start: 2009-11-30End: 2012-10-31Updated: 2017-04-07

Phase 4

A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)

CompletedNCT01756079

Merck Sharp & Dohme LLCHepatitis C

Start: 2013-02-06End: 2015-11-17Updated: 2018-09-05

A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)

WithdrawnNCT01770223

Merck Sharp & Dohme LLCHepatitis C

Start: 2014-01-31End: 2015-12-31Updated: 2017-03-20

Unknown Phase

Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)

CompletedNCT00724893

Merck Sharp & Dohme LLCHepatitis C, Hepatitis C, Chronic

Start: 2005-08-31End: 2012-08-31Updated: 2015-08-14

Journal of Clinical Oncology2019-05-204 citations

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

Clinical Cancer Research2018-01-2255 citations

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

2017-07-17178 citations

Abstract CT065: KEYNOTE 029: A phase I/II randomized trial of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma

Cancer Research2017-07-01

KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.

Journal of Clinical Oncology2017-05-2011 citations

Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study.

Journal of Clinical Oncology2017-02-206 citations

Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.

Journal of Clinical Oncology2016-05-2048 citations

Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC).

Journal of Clinical Oncology2016-05-206 citations

Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.

Journal of Clinical Oncology2015-05-2028 citations

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

2013-06-12140 citations